CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® in Children with Hereditary Angioedema
CSL Canada Announces First Canadian Patient Receives HEMGENIX® Hemophilia B Gene Therapy in Ontario, Canada
Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® Over Five Years
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance for Public Reimbursement of HEMGENIX® , the First Gene Therapy for Hemophilia B
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Bahia Metals Delivers 313 Million Tonnes of Inferred Mineral Resources at 0.33% Nickel Total Equivalent for Mangueiros Main Project
Apex Resources Receives TSX Venture Exchange Acceptance to Grant of Option to Tungsten Reserve Corp. to Explore and Mine Tungsten Zones in the Jersey-Emerald Project in BC
Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
